Skip to content

Released Nov 7, 2019, after the close

10-Q filed Nov 7, 2019, 38 days after period end · 0000950123-19-010301

Q3 2019 · 10-Q
Revenue$4.23M−1.3% vs Q3 2018+37.4% vs Q2 2019
Net Income-$25.00MN/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$0.96N/M vs Q3 2018N/M vs Q2 2019
Operating Income-$25,993,000N/M
Operating Cash Flowderived-$18,595,000N/M
Free Cash Flowderived-$18,595,000N/M
Margins · derived
Operating margin-614.3%−87.6 pt vs Q3 2018
Net margin-590.8%−88.3 pt vs Q3 2018

What the release said

The release

Same quarter

MetricQ3 2019Q3 2018Q3 2017Q3 2016
Revenue$4.23M$4.29M$2.66M—
Net Income-$25.00M-$21.54M-$12.27M-$11.57M
EPS Diluted-$0.96-$0.87-$710.00-$0.67

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR